Biomarkers of outcome to weekly paclitaxel in epithelial ovarian cancer.
Ainhoa Madariaga, Swati Garg, Jeffrey P Bruce...
https://pubmed.ncbi.nlm.nih.gov/32912664Actively Recruiting
Age: 18Years +
All Genders
ID03740503
Genomic Investigation of Unusual Responders in Cancer Patients
Led by University Health Network, Toronto · Updated on 2025-01-31
100
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying how tumors from the same patient can react very differently to the same chemotherapy drugs. This study focuses on understanding the genetic reasons for unusual responses—both exceptionally good and poor—to treatment. The goal is to identify genetic factors that explain why some tumors respond in unexpected ways by examining tumor DNA and molecular characteristics. The study involves analyzing stored tumor samples from patients who showed either an exceptional positive or negative response to cancer treatment. This includes using advanced DNA sequencing techniques, such as Exome sequencing, to investigate the genetic makeup of these tumors. Deceased patients' archived tissues may also be included if certain conditions are met. Participants provide tumor samples that researchers will analyze to characterize the tumor genomes over a period of up to two years. The study does not involve new treatments or interventions but focuses on understanding tumor genetics based on past treatment responses. This observational study helps to improve knowledge of cancer behavior and treatment reactions.
CONDITIONS
Brief Title
Genomic Investigation of Unusual Responders
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
- The patient must have an exceptionally good or poor response to treatment according to their doctor.
- Response may include complete response, partial response, or progression-free interval of at least 6 months.
- Exceptionally poor response includes unexpected poor outcomes like rapid tumor growth or death.
- The patient must have enough stored tumor tissue available for genetic sequencing.
- Deceased patients may be included if their stored tissue is accessible with proper consent or waivers.
You will not qualify if you...
- None
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Sample Collection
Duration - Up to 2 years
Participants provide stored tumor tissue samples for genomic analysis.
Trial Site Locations
Total: 1 location
1
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 2M9
Actively Recruiting
Loading map...
Research Team
C
Celeste Yu
E
Elizabeth Shah
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here